You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB01260
TypeSmall Molecule
GroupsApproved, Investigational

A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses. [PubChem]

11beta,21-Dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dioneNot AvailableNot Available
11beta,21-Dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dioneNot AvailableNot Available
11beta,21-Dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dioneNot AvailableNot Available
16alpha-Hydroxyprednisole-16,17-acetonideNot AvailableNot Available
16alpha-Hydroxyprednisolone-16alpha,17-acetonideNot AvailableNot Available
16alpha,17alpha-IsopropylidenedioxyprednisoloneNot AvailableNot Available
Desfluorotriamcinolone acetonideNot AvailableNot Available
DesonidaNot AvailableNot Available
DesonidumNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desowencream.5 mg/gtopicalGalderma Laboratories, L.P.1984-12-14Not AvailableUs
Desonidecream.5 mg/gtopicalActavis Mid Atlantic LLC2013-08-01Not AvailableUs
Desonategel.5 mg/gtopicalIntendis Inc.2010-01-28Not AvailableUs
Verdesoaerosol, foam.5 mg/gtopicalAqua Pharmaceuticals2006-10-06Not AvailableUs
Desonidecream.5 mg/gtopicalRebel Distributors Corp2006-04-11Not AvailableUs
Desonidecream.5 mg/gtopicalPerrigo New York Inc2006-04-11Not AvailableUs
Desonideointment.5 mg/gtopicalPerrigo New York Inc2006-08-22Not AvailableUs
Desonategel.5 mg/gtopicalBayer Health Care Pharmaceuticals Inc.2006-10-20Not AvailableUs
Desonidecream.5 mg/gtopicalPhysicians Total Care, Inc.2006-04-11Not AvailableUs
Desonideointment.5 mg/gtopicalPhysicians Total Care, Inc.2006-06-21Not AvailableUs
Desonidelotion.5 mg/gtopicalOwen Laboratories, Inc.1984-12-14Not AvailableUs
Desonidecream.5 mg/gtopicalOwen Laboratories, Inc.1984-12-14Not AvailableUs
Verdesoaerosol, foam0.05 %topicalGlaxosmithkline IncNot AvailableNot AvailableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desonideointment.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2010-10-19Not AvailableUs
Desonidelotion.5 mg/1000mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2002-03-19Not AvailableUs
Desowenlotion.5 mg/gtopicalGalderma Laboratories, L.P.1988-07-15Not AvailableUs
Lokaralotion.5 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2002-03-19Not AvailableUs
Desonidelotion.5 mg/mLtopicalActavis Mid Atlantic LLC, Lincolnton, NC 280922009-05-28Not AvailableUs
Desonidecream.5 mg/gtopicalRebel Distributors Corp1992-06-30Not AvailableUs
Desonidecream.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1992-06-30Not AvailableUs
Desonideointment.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1994-08-03Not AvailableUs
Desonidelotion.5 mg/mLtopicalTaro Pharmaceuticals U.S.A., Inc.2014-10-31Not AvailableUs
Desonidelotion.5 mg/gtopicalPhysicians Total Care, Inc.2004-05-17Not AvailableUs
Over the Counter ProductsNot Available
International Brands
Brand mixturesNot Available
SaltsNot Available
CategoriesNot Available
CAS number638-94-8
WeightAverage: 416.5073
Monoisotopic: 416.219888756
Chemical FormulaC24H32O6
Mass SpecNot Available
KingdomOrganic Compounds
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsKetosteroids; Hydroxysteroids; Cyclohexanols; 1,3-Dioxolanes; Cyclic Alcohols and Derivatives; Ketones; Enolates; Polyamines; Acetals; Primary Alcohols; Aldehydes
Substituents20-keto-steroid; 11-hydroxy-steroid; 3-keto-steroid; cyclohexanol; meta-dioxolane; cyclic alcohol; ketone; secondary alcohol; primary alcohol; enolate; ether; polyamine; acetal; carbonyl group; aldehyde; alcohol
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.
PharmacodynamicsDesonide is a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Mechanism of actionLike other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
AbsorptionTopical corticosteroids can be absorbed from normal intact skin, inflammation and/or other disease processes in the skin may increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9764
Blood Brain Barrier + 0.9382
Caco-2 permeable - 0.6162
P-glycoprotein substrate Substrate 0.7998
P-glycoprotein inhibitor I Non-inhibitor 0.5837
P-glycoprotein inhibitor II Inhibitor 0.6045
Renal organic cation transporter Non-inhibitor 0.7573
CYP450 2C9 substrate Non-substrate 0.8268
CYP450 2D6 substrate Non-substrate 0.9078
CYP450 3A4 substrate Substrate 0.7545
CYP450 1A2 substrate Non-inhibitor 0.909
CYP450 2C9 substrate Non-inhibitor 0.8729
CYP450 2D6 substrate Non-inhibitor 0.9544
CYP450 2C19 substrate Non-inhibitor 0.9521
CYP450 3A4 substrate Non-inhibitor 0.536
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9129
Ames test Non AMES toxic 0.8938
Carcinogenicity Non-carcinogens 0.949
Biodegradation Not ready biodegradable 0.9766
Rat acute toxicity 2.5316 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9573
hERG inhibition (predictor II) Non-inhibitor 0.67
ManufacturersNot Available
Dosage forms
Aerosol, foamtopical.5 mg/g
Aerosol, foamtopical0.05 %
Creamtopical.5 mg/g
Geltopical.5 mg/g
Lotiontopical.5 mg/1000mL
Lotiontopical.5 mg/g
Lotiontopical.5 mg/mL
Ointmenttopical.5 mg/g
Unit descriptionCostUnit
DesOwen Lot w/Cetaphil Cream 0.05% Kit Box255.84USDbox
Desowen 0.05% ointment kit217.2USDkit
Desowen 0.05% cream kit212.4USDkit
DesOwen 0.05% Lotion 118ml Bottle183.17USDbottle
Desonide powder152.39USDg
DesOwen 0.05% Lotion 59ml Bottle123.38USDbottle
Desonide 0.05% Lotion 118ml Bottle76.75USDbottle
Desonide 0.05% Lotion 59ml Bottle50.86USDbottle
Desonide 0.05% Ointment 60 gm Tube41.76USDtube
Desonide 0.05% Cream 60 gm Tube41.48USDtube
Desonide 0.05% Ointment 15 gm Tube16.09USDtube
Desonide 0.05% Cream 15 gm Tube16.07USDtube
Desowen 0.05% cream2.43USDg
Desonide 0.05% cream0.81USDg
Desocort 0.05 % Ointment0.32USDg
Pms-Desonide 0.05 % Cream0.28USDg
Pms-Desonide 0.05 % Ointment0.28USDg
Desocort 0.05 % Lotion0.16USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
CountryPatent NumberApprovedExpires (estimated)
United States63873832000-08-032020-08-03
United States67302881999-09-082019-09-08
Experimental Properties
melting point257-260Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to American Cyanamid Company. Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to E.R. Squibb & Sons, inc.
water solubilityPractically insolubleNot Available
logP1.4Not Available
Predicted Properties
Water Solubility0.0594ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity112.06 m3·mol-1ChemAxon
Polarizability44.77 Å3ChemAxon
Number of Rings5ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
SpectraNot Available
Synthesis Reference

Bernstein, S. and Allen, G.R., Jr.; U.S. Patent 2,990,401; June 27, 1961; assigned to
American Cyanamid Company.
Diassi, P.A. and Principe, P.A.; U.S.Patent 3,549,498; December 22, 1970; assigned to
E.R. Squibb & Sons, inc.

General ReferenceNot Available
External Links
KEGG DrugD03696
PubChem Compound5311066
PubChem Substance46506186
Therapeutic Targets DatabaseDAP001188
ATC CodesS01BA11D07AB08
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(73.7 KB)
Drug InteractionsNot Available
Food InteractionsNot Available


1. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist


Name UniProt ID Details
Glucocorticoid receptor P04150 Details


  1. Russell GM, Henley DE, Leendertz J, Douthwaite JA, Wood SA, Stevens A, Woltersdorf WW, Peeters BW, Ruigt GS, White A, Veldhuis JD, Lightman SL: Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci. 2010 Apr 28;30(17):6106-15. Pubmed
  2. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. Pubmed
  3. Otte C, Wust S, Zhao S, Pawlikowska L, Kwok PY, Whooley MA: Glucocorticoid receptor gene, low-grade inflammation, and heart failure: the Heart and Soul study. J Clin Endocrinol Metab. 2010 Jun;95(6):2885-91. Epub 2010 Apr 6. Pubmed

comments powered by Disqus
Drug created on May 16, 2007 11:31 / Updated on April 10, 2014 13:55